An observational study in Nodular Lymphocyte-Predominant Hodgkin Lymphoma, sponsored by St. Jude Children's Research Hospital. Recruiting at 7 sites in United States. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by St. Jude Children's Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital — 6 open to participants now, 13 under way, none of them phase 3. Hodgkin Disease · St. Jude Children's Research Hospital.
Among the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital, this one is one of 2 that started in 2024, is one of 9 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 23rd registered.
1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.
Browse Hodgkin Disease studies →6 of the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
St. Jude Children's Research Hospital · Sites in United States
Ages 10–25
St. Jude Children's Research Hospital · Sites in United States
Ages 18+ · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
St. Jude Children's Research Hospital · Sites in United States
Ages 12–24
By country, each count listing its studies:
Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 8 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 127 across 162 observational studies indexed under Hodgkin Disease.
Median enrollment 71 across the 18 interventional studies, 100 across the 9 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
3 of the studies in Hodgkin Disease by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06421987St. Jude Children's Research HospitalCardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors | 2026-12 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT00840047St. Jude Children's Research HospitalMethionine PET/CT Studies In Patients With Cancer | 2027-07-27 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Hodgkin Disease by St. Jude Children's Research Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There is a pressing need to measure patient-reported symptoms in patients of all ages diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). This study aims to measure longitudinal symptom burden and treatment tolerability utilizing validated patient-reported outcomes (PROs) instruments.
Primary Objective:
Secondary Objective:
The broad aim of this study is to develop the foundational data management infrastructure required to prospectively collect longitudinal electronic patient-reported outcomes (PROs) survey instruments in adult and pediatric patients diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The study team further aims to elucidate how PROs change over time and how they may be affected by different patient, disease, and treatment characteristics.
Patients that meet eligibility
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Estimates of response rates
Percentage of survey completion at different timepoints
Time frame: At baseline, 3, 6, 9, and 12 months
Patterns of individual per-patient survey completion
Patterns of individual per-patient survey completion will be described. Non-responders, late responders, and patients with suboptimal item completion rates who require real-time outreach will be queried for individual challenges in completing PRO surveys for iterative improvements to infrastructure.
Time frame: At baseline, 3, 6, 9, and 12 months
Started Apr 2024 (actual). Primary completion is estimated for Feb 2029, 58 months after the start.
Of 59 non-industry observational studies under Hodgkin Disease, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 149. This study's planned 58 months is close to that.
Counting every sponsor, half of 66 studies reached it within 61 months; a quarter within 34 and three quarters within 149.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Feb 2029 and completion Jan 2028 → Mar 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Jude Children's Research Hospital →